SCHEMBL6793095

SCHEMBL6793095

CC1(C(O)c2ccc(-c3cccc(OCc4ccccc4)c3)cc2)NC(=O)NC1=O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 3/20 0.47
MRGPRX4 Q96LA9 2/20 0.46
ALOX5 P09917 1/20 0.44
SOD1 P00441 1/20 0.44
MMP2 P08253 1/20 0.43
MMP13 P45452 1/20 0.43
NR4A2 P43354 1/20 0.43
HDAC4 P56524 1/20 0.43
MMP8 P22894 1/20 0.42
MMP14 P50281 1/20 0.42
FFAR1 O14842 3/20 0.42
ADAM17 P78536 2/20 0.42
GNA15 P30679 1/20 0.42
GSTP1 P09211 1/20 0.41
SMPD1 P17405 1/20 0.41
F9 P00740 1/20 0.41
F10 P00742 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6798530 0.87 MMP13 (0.56) ALOX5MMP2MMP13MMP14FFAR1
SCHEMBL6792382 0.84 PGR (0.48) DHODHHDAC4FFAR1
SCHEMBL6789361 0.82 MMP2 (0.41) MMP2MMP8
SCHEMBL6791153 0.82 MMP2 (0.41) MMP2MMP8
SCHEMBL6791227 0.82 MMP2 (0.41) MMP2MMP8
SCHEMBL6786669 0.81 MAPT (0.41)
SCHEMBL8343005 0.78 MMP3 (0.48) MMP2MMP8
SCHEMBL6792396 0.78 PTGER3 (0.46) ALOX5HDAC4GSTP1
SCHEMBL8339982 0.78 PGR (0.41) DHODHMMP2MMP13MMP8MMP14
SCHEMBL6835790 0.77 FFAR1 (0.41) DHODHMMP2MMP13FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040110809-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-10 US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
EP-1370538-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110809-A1 Metalloproteinase inhibitors MMP9, MMP2, MMP3 DHODH 1270/4885MRGPRX4 1354/4885ALOX5 912/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 DHODH 1457/4885MRGPRX4 904/4885ALOX5 1936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.